The world’s response to the COVID-19 pandemic required urgent and significant changes to the way new medications, vaccinations and medical devices are produced, tested and regulated. Some of these changes have proven successful and will outlast the pandemic. Join us as we discuss the impact COVID-19 has had on regulatory processes for medical devices, over both the short-term and suspected long-term.
In this session our experts will explore the following topics in the context of the medical devices and wider life sciences sector:
- The UK regulatory lifecycle: from pre-submission engagement to post-approval surveillance
- The impact of COVID-19: what changed and how this is expediting innovation for patients
- Key considerations for life sciences companies with products in development
- Early access schemes and approach
- Likely future trends and developments in the regulatory space.
Our guest panel will include:
John Brennan, VP Regulatory Affairs & Quality, Medtronic;
Graeme Tunbridge, Director of Medical Devices, MHRA;
Andy Flockhart, Deloitte UK MedTech Leader;
Fran Cousins, Deloitte Life Science Catalyst lead.
Please register via this link. I look forward to joining you for this informative session.
